Healthcare Industry News: Gabapentin GR
News Release - July 6, 2006
Depomed Names Matthew Gosling Vice President, Legal and General CounselMENLO PARK, Calif.--(HSMN NewsFeed)--July 6, 2006--Depomed, Inc. (NASDAQ:DEPO ) announced today that Matthew Gosling has joined the company as vice president, legal and general counsel. Mr. Gosling officially joins Depomed after serving as one of the company's outside legal counselors for the past several years while he was employed at Heller Ehrman LLP.
"Matt is a superb addition to our internal management team," said John W. Fara, Ph.D., chairman, president and chief executive officer of Depomed. "He has provided excellent counsel to us for many years, not only from a legal perspective, but also as a significant strategic resource for various aspects of our business. We are pleased to have him join our company and look forward to his continued contributions as we grow Depomed."
Mr. Gosling (35) was most recently a partner at Heller Ehrman LLP, where he served a nine-year tenure. At Heller Ehrman, he represented both public and private companies and provided legal counsel on general corporate matters, including SEC compliance and license and collaboration agreements, as well as many other business transactions. Mr. Gosling received his law degree from the University of Chicago and holds a B.A. from Trinity University, San Antonio.
Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm(TM) drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. Proquin® XR (ciprofloxacin hydrochloride) once daily, extended-release tablets have been approved by the FDA for the treatment of uncomplicated urinary tract infections. In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes have been approved in the U.S. and Canada. The company is conducting a Phase III trial in postherpetic neuralgia with its product candidate, Gabapentin GR(TM). Additional information about Depomed may be found at its web site, www.depomedinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our expectations regarding enrollment in clinical trials, our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.